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Relationship of Serum Fibrosis Markers with Liver
Fibrosis Stage and Collagen Content in Patients with
Advanced Chronic Hepatitis C
Robert J. Fontana,1 Zachary D. Goodman,2 Jules L. Dienstag,3 Herbert L. Bonkovsky,4 Deepa Naishadham,5
Richard K. Sterling,6 Grace L. Su,7 Mita Ghosh,1 Elizabeth C. Wright,8 and the HALT-C Trial Group
This study determined the utility of a panel of serum fibrosis markers along with routine labo-
ratory tests in estimating the likelihood of histological cirrhosis in a cohort of prior nonre-
sponders with chronic hepatitis C. The relationship between serum markers and quantitative
hepatic collagen content was also determined. Liver biopsy samples from 513 subjects enrolled in
the HALT-C trial were assigned Ishak fibrosis scores. The collagen content of 386 sirius-red
stained, nonfragmented biopsy samples was quantified using computerized morphometry. Se-
rum tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), amino-terminal peptide of type III
procollagen (PIIINP), hyaluronic acid (HA), and YKL-40 levels were determined using commer-
cially available assays.Sixty-two percent of patients had noncirrhotic fibrosis (Ishak stage 2-4)
whereas 38% had cirrhosis (Ishak stage 5,6). Multivariate analysis identified a 3-variable model
(HA, TIMP-1, and platelet count) that had an area under the receiver operating curve (AUROC)
of 0.81 for estimating the presence of cirrhosis. This model was significantly better than that
derived from the cirrhosis discriminant score (AUROC 0.70), the AST-to-platelet ratio (AUROC
0.73), and a prior model developed in HALT-C patients (AUROC 0.79). Multivariate analysis
demonstrated that the serum fibrosis markers correlated substantially better with Ishak fibrosis
scores than with the log hepatic collagen content (AUROC 0.84 versus 0.72). Conclusion: A
3-variable model consisting of serum HA, TIMP-1, and platelet count was better than other
published models in identifying cirrhosis in HALT-C Trial subjects. The stronger correlation of
the serum markers with Ishak scores suggests that serum fibrosis markers reflect the pattern of
fibrosis more closely than the quantity of hepatic collagen. (HEPATOLOGY 2008;47:789-798.)
Abbreviations: ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; CDS, cirrhosis discrimi-
nant score; CHC, chronic hepatitis C; CV, coefficient of variation; HA, hyaluronic acid; HALT-C, Hepatitis C Antiviral Long-term Treatment against Cirrhosis; HCV,
hepatitis C virus; INR, international normalized ratio; OR, odds ratio; PCR, polymerase chain reaction; PIIINP, amino-terminal peptide of type III procollagen; TIMP-1,
tissue inhibitor of matrix metalloproteinase-1.
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI; 2Armed Forces Institute of Pathology, Washington, DC; 3Gastrointestinal
Unit, Medical Services, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston, MA; 4Departments of Medicine and
Molecular and Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT; 5New England Research Institutes,
Watertown, MA; 6Hepatology Section, Virginia Commonwealth University Health System, Richmond, VA; 7Ann Arbor Veteran’s Administration Health Center, Ann
Arbor, MI; 8Office of the Director, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human
Services, Bethesda, MD.
Received July 11, 2007; accepted October 16, 2007.
This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (contract numbers are listed at the end of the article). Additional support
was provided by the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute, the National Center for Minority Health and Health
Disparities, and by General Clinical Research Center grants from the National Center for Research Resources, National Institutes of Health (grant numbers are listed at the
end of the article). Additional funding to conduct this study was supplied by Hoffmann-La Roche Inc., through a Cooperative Research and Development Agreement
(CRADA) with the National Institutes of Health.
Dr. Bonkovsky’s current address is: Cannon Research Center, Suite 201, Carolinas Healthcare System, Charlotte, NC, 28203.
This is publication number 26 of the HALT-C study group.
Address reprint requests to: Robert Fontana, Department of Internal Medicine, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI
48109-0362. E-mail: rfontana@umich.edu; fax: 734-936-7392.
Copyright © 2008 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/hep.22099
Potential conflict of interest: Financial relationships of the authors with Hoffmann-La Roche Inc., are as follows: R.J. Fontana is on the speaker’s bureau; R.K. Sterling
is a consultant and on the speaker’s bureau; Authors with no financial relationships related to this project are: Z.D. Goodman, J.L. Dienstag, D. Naishadham, Grace Su,
Mita Ghosh, H.L. Bonkovsky, and E.C. Wright.
789
The severity of hepatic fibrosis and inflammation atdiagnosis correlates strongly with the likelihoodof disease progression in patients with chronic
hepatitis C (CHC).1,2 In addition, histologic staging in
patients with CHC influences disease monitoring as well
as antiviral treatment decisions.3,4 For example, according
to treatment guidelines, antiviral therapy is a high priority
for patients with moderate to severe fibrosis on liver bi-
opsy. In the same vein, subjects with bridging fibrosis or
cirrhosis should undergo surveillance for esophageal var-
ices and hepatocellular carcinoma.5,6 Therefore, assess-
ment of disease stage is an integral part of the evaluation
and management of patients with CHC worldwide.
Liver biopsy is currently considered the “gold stan-
dard” for assessing disease severity and stage in patients
with various forms of chronic liver disease. However, lim-
itations of liver biopsy include sampling error, understag-
ing, and interobserver variability in interpretation.7-9 In
one study of simultaneous right and left lobe laparoscopic
liver biopsies, a discordance of at least 1 fibrosis stage was
identified in 24% of the biopsies and understaging of
cirrhosis in 14%.8 Furthermore, because of its risks, in-
convenience, and costs, serial liver biopsy is not practical
to monitor disease progression and treatment effect.
Therefore, developing noninvasive tests that can accu-
rately predict initial disease stage and fibrosis progression
over time represents a high priority and growing medical
need.10 Routinely obtained blood tests such as serum as-
partate aminotransferase (AST), AST/alanine amino-
transferase (ALT) ratio, and platelet count levels have
been proposed as indirect markers of advanced fibrosis in
patients with CHC.11-15 Although widely available, these
laboratory tests do not reliably distinguish between indi-
vidual stages of fibrosis nor the presence of advanced fi-
brosis with a high level of certainty. In addition, none of
the blood tests included in these panels directly reflect the
pathophysiology of hepatic fibrogenesis mediated by he-
patic stellate cells.16 Panels of serum fibrosis markers such
as hyaluronic acid (HA), amino-terminal peptide of type
III procollagen (PIIINP), tissue inhibitor of matrix met-
alloproteinase inhibitor-1 (TIMP-1), and YKL-40 are be-
lieved to more directly reflect the resorption of low-
density extracellular matrix and deposition of high-
density matrix in patients with chronic liver disease.17-19
Cross-sectional studies suggest that some of these serum
fibrosis markers, either individually or in combination,
may provide important disease staging information such
as the presence or absence of advanced fibrosis or cirrho-
sis.17
The Hepatitis C Antiviral Long-term Treatment
against Cirrhosis (HALT-C) Trial is a prospective multi-
center study designed to investigate the potential benefit
of maintenance peginterferon therapy in reducing the rate
of clinical outcomes and histological progression in prior
interferon nonresponders with advanced fibrosis.20,21 The
aim of the current study was to determine the utility of a
panel of serum fibrosis markers including serum PIIINP,
TIMP-1, HA, and YKL-40 in estimating initial disease
stage in 513 subjects enrolled in the HALT-C trial. In
addition, the relationship between serum fibrosis markers
and the quantitative assessment of hepatic collagen con-
tent as measured by computerized morphometry was de-
termined.22,23 Finally, the accuracy of models derived
from our study population that incorporated serum fibro-
sis markers and routine laboratory tests were compared to
the results obtained with other published models based
solely on standard laboratory tests.
Patients and Methods
Patient Population. Inclusion criteria for the
HALT-C Trial include the presence of detectable serum
hepatitis C virus (HCV) RNA, a liver biopsy within 12
months of enrollment demonstrating bridging hepatic fi-
brosis (that is, an Ishak fibrosis score 3) or cirrhosis, and
lack of a sustained response to a prior course of interferon
with or without ribavirin.20,21 All patients underwent a
pretreatment liver biopsy to confirm the presence of at
least bridging fibrosis (that is, an Ishak fibrosis score 3).
All baseline liver biopsies were obtained at least 2 months
after completing prior interferon therapy in patients that
had failed to clear HCV RNA. Subjects were retreated
with peginterferon alfa-2a and ribavirin for 24 weeks in
the “lead-in phase” of the study. Subjects who remained
viremic at week 20 were eligible for entry into the ran-
domized phase of the HALT-C trial whereas subjects with
undetectable HCV RNA by polymerase chain reaction
(PCR) continued in the “responder arm” of the study and
completed a 48-week course of combination antiviral
treatment. All participants entering the lead-in phase of
the HALT-C Trial enrolled at the University of Michi-
gan, University of Massachusetts/University of Connect-
icut, Massachusetts General Hospital, and the Virginia
Commonwealth University had extra serum collected for
this ancillary study. Serum was isolated from whole blood
samples within 1 hour of collection and frozen immedi-
ately at 80°C. Samples were batch-shipped on dry ice
and stored at a central repository (Seracare, Washington,
DC). The study was approved by local Institutional Re-
view Boards, and all patients provided written informed
consent.
Baseline Evaluation. Laboratory tests included com-
plete blood counts, liver panel (AST, ALT, serum biliru-
bin, alkaline phosphatase, albumin), prothrombin time/
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international normalized ratio (INR), and tests to exclude
other causes of liver disease. HCV genotype and quanti-
tative HCV RNA levels were performed by a central lab-
oratory (University of Washington, Seattle, WA).20,21
Serum AST, ALT, and alkaline phosphatase levels were
expressed as a ratio of the upper limit of normal based on
the reference range of each local hospital laboratory. Liver
ultrasounds and upper endoscopies were performed in the
participating clinical centers.6 Lifetime alcohol consump-
tion was determined using the modified Skinner survey.20
Liver Histology. Baseline liver biopsies were reviewed
by a committee of hepatopathologists representing the 10
clinical centers. The modified histological activity index
(also known as the Ishak score) was chosen as the principal
scoring system.24 Fibrosis scores were evaluated with the
Masson trichrome stain and determined by committee
consensus. Biopsies were recorded as fragmented when
the specimen had broken into multiple small rounded
pieces that were usually less than 2 mm in maximal diam-
eter. A small number of patients (n  41) with a biopsy
showing stage 2 fibrosis but with a prior biopsy showing
stage 3 were included in HALT-C. For analysis pur-
poses, biopsies were grouped as Ishak 2, 3, or 4 (precir-
rhotic fibrosis) versus Ishak 5 or 6 (cirrhosis). Hepatic
steatosis was graded using a semi-quantitative grading
scheme as follows: 0 (1%), 1 (1%- 5%), 2 (6%-33%), 3
(34%-67%), 4 (67% of hepatocytes showing fat) using
previously described methods.25
Morphometric Image Analysis of Hepatic Fibrosis.
Sections of each liver biopsy stained with sirius red were
used for assessment of hepatic collagen content as previ-
ously described using Image Pro Plus 6.0 imaging soft-
ware (Media Cybernetics, Silver Spring, MD).26 The
method is based upon the observation that the degree of
sirius red staining measured by the saturation of the red
channel correlates well with chemically determined colla-
gen content and morphometrically determined estimates
of the area of hepatic fibrosis. The collagen content per
unit area of the specimen is expressed in arbitrary units
calculated as the sum of the pixel-wise collagen measure-
ments divided by the number of summed pixels and is
directly proportional to the thickness of the tissue section.
Therefore, the collagen content per unit area was divided
by the section thickness in microns measured with a con-
focal laser scanning microscope (Zeiss LSM 310) to yield
the final result that was reported in arbitrary units per
volume of tissue that can be used for comparison of indi-
vidual samples and in statistical calculations. Because
most liver histologic sections are 4 to 6 m thick, the
arbitrary collagen units were multiplied by 5 to create
units with a range of 0 to 0.35. Because computerized
morphometry of fragmented liver biopsies tends to un-
derestimate the amount of hepatic fibrosis and provide
inaccurate results, only the data obtained from the 386
patients with nonfragmented liver biopsies were included
in this analysis.
Serum TIMP-1 Assay. Serum TIMP-1 was measured
using a commercial ELISA kit (Quantikine, R&D Sys-
tems, Minneapolis, MN). Serum samples were diluted
100-fold and run as singlets on a 96-well microplate. The
intra-assay coefficient of variation (CV) was 3.6% and the
interassay CV was 5.6%. Samples below the lower limit of
detection of 1.0 ng/mL were repeated and samples that
were above the upper limit of quantitation of 500
ng/mL were retested using another aliquot at a dilution of
1:2.
Serum PIIINP Assay. Intact N-terminal propeptide
of type III procollagen (PIIINP) levels were measured
using a commercial RIA kit (UniQ, Orion Diagnostica,
Espoo, Finland). Briefly, undiluted serum samples were
run as singlets in glass tubes in batches of 42 samples. The
intra-assay CV was 3.4% and the interassay CV was
7.3%. Samples below the lower limit of detection of 
1.0 g/L were repeated. Samples that exceeded the upper
limit of quantitation of 15 g/L were retested using a
dilution of 1:10.
Serum YKL-40 Assay. YKL-40 also known as human
cartilage glycoprotein 39 is a 40-kilodalton glycoprotein
that is believed to be involved in tissue remodeling.27
Serum YKL-40 levels were determined using a commer-
cial ELISA kit (Metra YKL-40, Quidel Corp., San Diego,
CA). Undiluted serum samples were run as singlets on
microplates and the intra-assay CV was 3.5% and the
interassay CV was 6%. Samples that exceeded the upper
limit of quantitation of 300 g/L were retested after a
1:10 dilution.
Serum Hyaluronic Acid Assay. Serum hyaluronic
acid (HA) levels were determined by an automated im-
munoassay, using liquid-phase binding assay technology
(LBA) on the LiBASys analyzer (Wako Diagnostics, Rich-
mond, VA). An undiluted serum sample was automati-
cally aspirated and added to a reagent containing
hyaluronic acid binding protein (HABP) and a peroxidase
labeled anti-HABP monoclonal antibody.28 The resulting
immune complexes were separated from the remaining
free-labeled antibody with an anion-exchange column
and the peroxidase activity of the bound fraction was mea-
sured using a fluorescent substrate. The assay is linear for
HA concentration of 10-1000 ng/mL; samples exceeding
1000 ng/mL were retested after a 1:10 dilution.
Statistical Methods. The individual serum fibrosis
marker data were imported as whole datasets from the
University of Michigan research laboratory and Wako
Diagnostics into a secure internet-based website main-
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tained by the data coordinating center (New England
Research Institute, Watertown, MA). Non-normally dis-
tributed variables were log-transformed when necessary.
Logistic regression modeling was used to identify a mul-
tivariate model that predicted the presence of cirrhosis in
all 513 HALT-C Trial patients. We then compared the
area under the receiver operating curve (AUROC) of our
model to that derived from standard laboratory tests pub-
lished in the literature including a previously reported
model based on platelets, INR, and AST/ALT developed
from baseline data in 1141 HALT-C Trial patients (Lok
model), the APRI, and the cirrhosis discriminant score
(CDS).12,14,15 The specific equation for the Lok model is:
Log odds  -5.56 -0.0089  platelet (103/mL) 
1.26  AST/ALT  5.27  INR and the predicted prob-
ability of cirrhosis is: exp ((logodds)/(1  exp (logodds)).
The CDS is a summary score of platelets (0 to 6
points), ALT/AST ratio (0 to 3 points), and INR (0 to 2
points) with scores 8 predicting presence of cirrhosis.12
Logistic regression was used to compare AUROC among
the different models. Because 31% of the 386 patients
with computerized morphometry had histological cirrho-
sis, we modeled the presence of high log-hepatic collagen
content by dividing this patient population into similar
proportions.
Results
Overall Patient Population. A total of 515 subjects
were enrolled into the lead-in phase of the HALT-C Trial
at the 4 participating sites; two were excluded from this
analysis because of inadequate liver biopsies. The clinical
features of the 513 participants included cirrhosis (Ishak
5/6) in 193 subjects (38%), Ishak 2 in 38 subjects (7.4%),
Ishak 3 in 189 subjects (37%), and Ishak 4 in 93 subjects
(18%) (Table 1). The majority of subjects were male
(71%), mean (standard deviation [SD]) age was 49.4
(7.1) years, and 75% were non-Hispanic Caucasians. Par-
ticipants included 66% who were nonresponders to prior
interferon and ribavirin combination therapy, 27% with
diabetes mellitus, and 30% with a body mass index (BMI)
exceeding 30 kg/m2. The mean serum AST level was 2.25
times the upper limit of normal and the mean (SD) plate-
let count was 172 (65)  103/L.
Serum Fibrosis Markers and Ishak Fibrosis Scores.
The mean values of serum PIIINP, HA, TIMP-1, and
YKL-40 were significantly higher in subjects with cirrho-
sis compared to those with noncirrhotic fibrosis (Table 1).
On univariate analysis, nearly all of the tested variables
were independent predictors of cirrhosis with log HA hav-
ing the highest odds ratio (Table 2). On multivariate anal-
ysis, a model consisting of serum TIMP-1, log HA, INR,
and platelet count had an AUROC of 0.83 (95% confi-
dence interval [CI]: 0.79-0.87). When we simplified the
model to 3 variables after removing INR, a 3-variable
HALT-C model had an AUROC of 0.81 (0.77, 0.85).
The 3-variable model was significantly better than any of
the individual serum fibrosis markers alone in estimating
the presence of cirrhosis (Table 2). In addition, the AU-
ROC of our 3-variable model was significantly better at
predicting the presence of cirrhosis compared to other
published models that use standard laboratory tests in-
cluding the APRI, CDS, and Lok model (Fig. 1). The
regression formula for the new 3-variable model is as fol-
lows: logodds (cirrhosis)  3.66  0.00995  platelets
(103/mL)  0.008  serum TIMP-1  1.42  log (HA).
In order to optimize the estimation of the absence of
cirrhosis from the AUROC, a cut-off of 0.2 leads to a
sensitivity of 88% with a NPV of 86% (Table 3). Simi-
larly, to estimate the presence of cirrhosis, a cut-off of
0.5 gives a specificity of 92% with a PPV of 78%.
Therefore, use of the 3-variable model in the HALT-C
Trial patients could have reduced the need for liver biopsy
in 153 (30%) subjects who were predicted to have a low
likelihood of cirrhosis with an accuracy of 86% and 146
(28%) patients with a high likelihood of cirrhosis with an
accuracy of 73%.
The 3-variable model performed better in subjects
with longer biopsies (that is, 1.5 cm in length compared
to 1.5 cm). Similarly, the AUROC of the model was
consistently higher in subjects with larger biopsy samples
that contained a greater number of portal triads and in
subjects without fragmented liver biopsy samples
(Table 4).
Computerized Morphometry Patient Population.
Computerized morphometry was performed on nonfrag-
mented liver biopsy slides from 386 subjects. Figure 2
demonstrates the variability in hepatic collagen content
between patients with differing stages of fibrosis. Because
the hepatic collagen levels were skewed toward lower lev-
els, the log-hepatic collagen value was used for analyses.
The 386 subjects with computerized morphometry data
tended to have less advanced fibrosis and a lower fre-
quency of cirrhosis than the overall group of 513 patients
due to the exclusion of subjects with fragmented biopsies
(31% versus 38% cirrhosis) (Table 1). As expected, they
also had higher platelet counts, a lower frequency of var-
ices, and laboratory abnormalities consistent with less se-
vere liver disease and portal hypertension. Figure 3 shows
a significant relationship between the log-hepatic collagen
content and the Ishak fibrosis scores (r  0.48, P 
0.001, Spearman correlation coefficient). However, there
was also substantial overlap in the values of log hepatic
collagen content and Ishak fibrosis scores. When we com-
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pared the 121 subjects with cirrhosis and interpretable
computerized morphometry scores to the 72 subjects with
cirrhosis and fragmented liver biopsies in whom mor-
phometry analysis was precluded, the patients in whom
morphometry was done had similar platelet counts, AST
levels and values for most other laboratory tests (Data not
shown). Exceptions, however, were the INR (1.06  0.08
versus 1.11  0.11, P  0.0001) and serum PIIINP levels
(6.90  2.62 versus 7.86  2.69, P  0.021) of patients
with cirrhosis with morphometry which were signifi-
cantly lower compared to patients with cirrhosis who were
excluded from the morphometry analysis, suggesting that
the liver disease in the former group was milder.
Serum Fibrosis Markers and Hepatic Collagen
Content. Because the log-hepatic collagen content is re-
ported as a continuous variable, we used correlational
analyses to identify predictors of log-hepatic collagen con-



















Age (years) 49.4 48.8 50.3 0.0157 49.16 0.25
% Female 29% 29% 28% 0.78 31% 0.0379
Ethnicity
% Caucasian 75% 76% 75% 0.75 73% 0.0323
% African-American 19% 18% 21% 0.4 22% 0.0302
% Hispanic 4% 4% 4% 0.67 5% 0.26
Duration of infection (years) 27.0 26.6 27.8 0.11 26.8 0.17
Duration of alcohol (years) 19.5 18.5 21.2 0.0116 19 0.0745
Lifetime alcohol consumption (drinks) 18024 17812 18375 0.83 17496 0.46
Lifetime smoking (pack-years) 15.1 14.9 15.5 0.67 15.2 0.78
% Diabetes 27% 24% 33% 0.0406 28% 0.50
% BMI  30 kg/m2 40% 38% 42% 0.38 39% 0.60
Mean BMI (kg/m2) 29.5 29.5 29.7 0.74 29.5 0.63
% Splenomegaly on ultrasound 32% 27% 40% 0.0021 31% 0.49
% Esophageal varices 17% 7% 30% 0.0001 13% 0.0054
% Prior IFN  ribavirin 66% 65% 68% 0.46 65% 0.17
Log HCV RNA (IU/mL) 6.44 6.5 6.34 0.001 6.43 0.64
% Genotype 1 89% 88% 91% 0.31 89% 0.75
AST ( ULN) 2.25 1.98 2.7 0.0001 2.21 0.41
ALT ( ULN) 2.23 2.15 2.35 0.19 2.23 0.97
AST/ ALT 0.86 0.8 0.97 0.0001 0.86 0.58
Alkaline phosphatase ( ULN) 0.87 0.8 0.99 0.0001 0.87 0.61
T. Bilirubin (mg/dL) 0.76 0.7 0.86 0.0001 0.76 0.94
INR 1.04 1.01 1.08 0.0001 1.02 0.0001
Albumin (g/dL) 3.85 3.94 3.7 0.0001 3.86 0.27
Platelets (103/mL) 172 190 142 0.0001 178 0.0002
White blood count (cells/mL) 6.05 6.17 5.84 0.0673 6.08 0.47
Log YKL-40 (g/L) 2.42 2.32 2.59 0.0001 2.42 0.88
Log HA (ng/mL) 1.96 1.78 2.24 0.0001 1.93 0.0175
Serum PIIINP (g/L) 6.2 5.44 7.5 0.0001 6.12 0.24
Serum TIMP-1 (ng/ml) 240.8 221.7 272.8 0.0001 239.2 0.37
Biopsy specimen length (cm) 1.84 1.92 1.71 0.006 1.95 0.0001
Mean Ishak fibrosis score 4.04 3.18 5.46 0.0001 3.88 0.0001
% Hepatic steatosis  2 41% 38% 48% 0.0254 41% 0.70
% Fragmented biopsies 22% 14% 36% 0.0001 0% NA
Data reported as mean or %
*P value  0.05 for 126 HALT-C subjects without morphometry data versus the 386 with evaluable morphometry scores
Table 2. Logistic Regression Models Predicting Cirrhosis
(Ishak 5/6) in the Overall Population
Characteristic
Univariate Odds
ratio * (95% CI) P value
AST ratio 1.51 (1.21,1.88) 0.0003
AST/ALT 1.78 (1.45,2.20) 0.0001
Alkaline phosphatase ratio 1.60 (1.31,1.95) 0.0001
Total bilirubin 1.43 (1.17,1.75) 0.0005
Albumin 0.50 (0.40,0.62) 0.0001
Hemoglobin 0.82 (0.68,0.99) 0.0406
White blood count 0.82 (0.67,1.00) 0.05
Log HCV RNA 0.77 (0.64,0.93) 0.0069
Spleen size 1.38 (1.15,1.67) 0.0006
PIIINP 2.34 (1.85,2.95) 0.0001
YKL-40 1.82 (1.49,2.23) 0.0001
TIMP-1 2.22 (1.77,2.79) 0.0001
Log HA 3.21 (2.49,4.14) 0.0001
INR 2.11 (1.69,2.64) 0.0001
Platelets 0.40 (0.32,0.51) 0.0001
*Models were developed in 471 HALT-C patients with complete data available.
HEPATOLOGY, Vol. 47, No. 3, 2008 FONTANA ET AL. 793
tent (Table 5). On univariate analyses, nearly all of the
laboratory variables tested were significantly associated
with the log-hepatic collagen content. Because 31% of the
386 patients with evaluable log-hepatic collagen were
known to have cirrhosis based on histological diagnosis,
we then divided the population into the upper 31% with
high hepatic collagen content and the lower 69%. Using
logistic regression, serum TIMP-1 (odds ratio [OR]:
1.004 (CI: 1.001, 1.008), P  0.02), alkaline phospha-
tase ratio (OR: 3.0 (CI: 1.63, 5.53), P  0.0004), and
platelets (OR: 0.61 (CI: 0.47, 0.79), P  0.0002) were
identified as independent predictors of high log-hepatic
collagen content with an overall c-statistic of 0.72 (CI:
0.67, 0.78). Interestingly, when we modeled the presence
of histological cirrhosis by light microscopy, which was
identified in 109 of these 386 subjects, a different model
consisting of serum PIIINP, TIMP-1, log HA, AST/
ALT, and platelet count was identified that had a substan-
tially higher AUROC of 0.84 (CI: 0.80, 0.89). Therefore,
the serum fibrosis markers correlated better with the pres-
ence of cirrhosis on light microscopy than log-hepatic
collagen content in the same group of patients.
Discussion
In this study, a large group of well-characterized CHC
patients with advanced fibrosis who were nonresponders
to interferon were prospectively studied. Liver histology
was scored according to the Ishak fibrosis system and he-
patic collagen content was assessed using computerized
morphometry. In addition to testing routine laboratory
variables, the utility of serum PIIINP, YKL-40, HA, and
TIMP-1 levels in estimating cirrhosis was determined.
Multiple studies have demonstrated a moderate to strong
correlation of serum PIIINP levels with hepatic inflam-
mation and fibrosis stage in patients with CHC.27 Serum
HA is a glycosoaminoglycan that can increase as a result of
activated hepatic stellate cell production or reduced he-
Fig. 1. AUROC for predicting the presence of cirrhosis in HALT-C
patients. A 3-variable model derived from our dataset consisting of
TIMP-1, log HA, and platelet count had an AUROC of 0.81 which was
significantly better than that achieved with the APRI, CDS, or Lok model
alone.








without Cirrhosis Sensitivity* Specificity* PPV* NPV*
0.1 64 3 (5%) 61 (95%) 98 21 43 95
0.1-0.2 89 18 (20%) 71 (80%) 88 45 49 86
0.2-0.3 77 16 (21%) 61 (79%) 79 66 58 84
0.3-0.4 55 14 (25%) 41 (75%) 71 80 68 82
0.4-0.5 40 19 (48%) 21 (53%) 60 87 73 78
0.5-0.6 38 23 (61%) 15 (39%) 47 92 78 74
0.6-0.7 33 22 (67%) 11 (33%) 35 96 83 71
0.7-0.8 39 29 (74%) 10 (26%) 19 99 92 67
0.8-0.9 23 21 (91%) 2 (9%) 7 100 92 64
0.9 13 12 (92%) 1 (8%) 0 100 . 62
*Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for a cutoff of  compared to 
Data derived from 177 HALT-C Trial patients with cirrhosis and 294 HALT-C Trial patients with Ishak 2-4.
Table 4. Application of the 3-Variable Model to Identify
Cirrhosis (Ishak 5/6) in Relationship to Liver Biopsy Size
Biopsy length < 1.5 cm > 1.5 cm
Number of patients 169 301
Number with cirrhosis (%) 67 (40%) 110 (37%)
AUROC 0.768 0.833
(95% CI) (0.695, 0.842) (0.785, 0.882)
No. of portal triads < 14 > 14
Number of patients 216 223
Number with cirrhosis (%) 89 (41%) 77 (35%)
AUROC 0.805 0.847
(95% CI) (0.745, 0.866) (0.795, 0.899)
Fragmented Biopsies Yes No
Number of patients 109 374
Number with cirrhosis (%) 66 (61%) 117 (31%)
AUROC 0.788 0.817
(95% CI) (0.701, 0.875) (0.770, 0.863)
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patic sinusoidal endothelial cell clearance.16,17,28 Serum
TIMP-1 is an inhibitor of circulating matrix metallopro-
teinases that can increase as fibrogenesis is activated. The
biology of YKL-40 is less well understood, but both cross-
sectional and longitudinal studies have demonstrated a
moderate to strong correlation between serum YKL-40
levels and fibrosis severity and progression over time in
CHC patients.19 More recent studies have demonstrated
that a combination of serum fibrosis markers with or
without other host variables may be a more accurate
means of estimating fibrosis severity, although longitudi-
nal validation studies in large groups of patients are lack-
ing.16,17
On univariate analysis, nearly all of the laboratory and
clinical variables that we tested were significantly associ-
ated with the presence of cirrhosis (Table 1). However,
only 4 laboratory tests were independently associated with
cirrhosis using logistic regression. Interestingly, this
4-variable model included 2 serum fibrosis markers
(TIMP-1, log HA) as well as 2 routinely obtained labora-
tory tests (INR, platelets). Identification of serum HA as a
strong and independent correlate of cirrhosis in CHC is
consistent with prior studies.16,17 One of the goals of this
analysis was to develop a model potentially useful to cli-
nicians; we found that a simplified 3-variable model that
excluded the INR performed nearly as well. The 3-vari-
able model was significantly better at identifying cirrhosis
than previously described models that exclusively rely on
routine laboratory tests (Fig. 1). Therefore, measurement
of serum hyaluronic acid, TIMP-1, and platelet counts
can help identify CHC patients with cirrhosis who should
Fig. 2. Biopsies that illustrate the dissociation between fibrosis stage
and hepatic collagen content. The specimen on the left is Ishak fibrosis
stage 3 with some very large fibrotic portal areas and occasional bridges
but not cirrhosis; its collagen content by morphometry is 0.0205 units
(sirius red stain). The biopsy in the center has cirrhosis, Ishak stage 6,
with thin septa and a collagen content of 0.0112 units, whereas the
biopsy on the right also has stage 6 fibrosis, but much more collagen,
0.521 units.
Fig. 3. Box plot of the log hepatic collagen content versus Ishak
fibrosis scores in 387 HALT-C Trial patients. Outliers are indicated with
circles whereas the mean is indicated with the dashed line. The median
is the solid line in the box that represents the interquartile range. The
correlation between these variables was significant (R2  0.22, P 
0.0001). However, there was also substantial overlap in the log hepatic
collagen values among patients with differing Ishak fibrosis scores.
Table 5. Correlational Analyses of Laboratory Parameters







AST/ ALT 0.244 (0.0001)
Alkaline phosphatase 0.256 (0.0001)




Log YKL-40 0.211 (0.0001)




Lok model 0.315 (0.0001)
CDS model 0.213 (0.0001)
*Analyses conducted in the 351 HALT-C patients with evaluable computerized
morphometry data and corresponding laboratory data.
HEPATOLOGY, Vol. 47, No. 3, 2008 FONTANA ET AL. 795
be monitored more closely for complications of cirrhosis
and liver cancer. The AUROC of our model was very
good (0.81) and would allow the correct categorization of
153 HALT-C patients as having a low likelihood of cir-
rhosis with 86% accuracy and 146 subjects with a high
likelihood of cirrhosis with 73% accuracy. However, 42%
of the HALT-C Trial subjects are predicted to have an
intermediate probability of cirrhosis. The AUROC could
have potentially been higher had it not been for the con-
founding effect of previous interferon therapy on serum
fibrosis marker expression.33,34 In addition, only subjects
with advanced fibrosis were allowed into the HALT-C
Trial so it is possible that the serum fibrosis markers
would have performed better if subjects with Ishak fibro-
sis scores of 0 to 6 had been included, highlighting the
need for additional validation studies in broader, patient
populations. Finally, individual biopsy samples may have
been misclassified as a result of sampling error which can
lead to understaging of fibrosis and cirrhosis. In support
of this, our model performed better in subjects without
fragmented biopsies and in patients with larger biopsy
samples (Table 4).35,36
The serum fibrosis markers also correlated with the
log-hepatic collagen content as determined by computer-
ized morphometry. Prior studies have shown that mor-
phometry is more sensitive for detecting changes in total
hepatic fibrosis during antiviral therapy compared to light
microscopy and strongly correlates with chemical deter-
mination of liver hydroxyproline content.23,26,29,37,38
Morphometric analysis of hepatic collagen content, how-
ever, is also limited by potential sampling variability and
morphometry is unreliable in subjects with fragmented
biopsies. The correlation between Ishak fibrosis scores
and log-transformed morphometry scores was significant
but substantial overlap among individual fibrosis stages
was apparent indicating that these measurements are not
the same (Fig. 3). Nevertheless, the correlation observed
between morphometry and Ishak fibrosis scores was sim-
ilar to that reported in other studies of CHC patients and
a broader range of fibrosis.30-32 Thus, the information
provided by computerized morphometry is likely comple-
mentary to that provided by light microscopy staging.
Nonetheless, because computerized morphometry is
more objective, reproducible, and quantitative than Ishak
fibrosis scores, it was anticipated that the serum markers
would correlate more strongly with morphometric colla-
gen content than with Ishak fibrosis scores.32 However,
the AUROC for identifying subjects with a high log he-
patic collagen content was substantially lower than that
obtained based on Ishak fibrosis scores in the 386
HALT-C Trial patients (0.72 versus 0.84). Therefore, if
the serum markers and laboratory tests used in our model
accurately reflect hepatic fibrogenesis, our observations
suggest that the pattern of collagen deposition as mea-
sured by the Ishak score is more reflective of disease sever-
ity and stage than the absolute amount of collagen in the
biopsy. Potentially contributing to the discordance be-
tween fibrosis pattern and collagen content is the substan-
tial proportion of HALT-C Trial patients who had
diabetes mellitus, obesity, or high lifetime alcohol con-
sumption (Table 1). These conditions are associated with
hepatic steatosis and perisinusoidal hepatic collagen dep-
osition which may increase the hepatic collagen content
but not influence Ishak fibrosis scores. However, hepatic
steatosis scores were not associated with hepatic collagen
content (P  0.21) even though there was a significant
correlation between each of the serum fibrosis markers
tested and the hepatic steatosis grade (P  0.0001 for
YKL-40, HA, TIMP-1, and PIIINP with hepatic steatosis
grade, data not shown).
Several limitations of our study should be acknowl-
edged. Firstly, the models were not tested in an external
validation cohort to confirm and refine them. Because the
HALT-C cohort is so unique, an independent cohort of
CHC patients with advanced but compensated fibrosis
for comparison who also had stored serum available for
testing could not be identified. An alternative strategy
would have been to develop a test and validation set from
this subgroup of HALT-C patients. However, the limited
number of patients with computerized morphometry
data of 386 precluded us from doing this. Therefore, it is
possible that we may have “overfit” our data and indepen-
dent validation of the proposed serum marker algorithims
is needed. In addition, we were not able to differentiate
among the individual Ishak fibrosis stages (that is, Ishak 2
from 3, and so forth); however, we felt that grouping
fibrosis scores together would help reduce sampling error.
Furthermore, the serum fibrosis markers tested are pro-
duced in multiple tissues throughout the body which can
lead to spurious elevations. For example, serum HA and
YKL-40 levels increase in subjects with active rheumato-
logical conditions and in subjects with renal insufficien-
cy39; however, both conditions were rare in our
population. Moreover, the serum markers evaluated,
which reflect active fibrogenesis and/ or fibrolysis rather
than the static amount of collagen or scar that has accu-
mulated in the liver, are not as good at estimating disease
stage. Nonetheless, the correlation among all of the indi-
vidual markers tested with the Ishak fibrosis scores was
good (Table 1). Finally, the inclusion of the serum mark-
ers improved our ability to identify subjects with cirrhosis
and our 3-variable algorithim was superior to that ob-
tained using routine laboratory tests (Fig. 1). Although
statistically significant, however, the overall increment at-
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tributable to the serum fibrosis markers was modest and
less than anticipated. Finally, it would have been desirable
to compare our algorithim to that obtained using other
models that include serum fibrosis markers such as the
Fibrotest, Fibrometer, and Hepascore.40,41 However, be-
cause serum samples were not prospectively assayed for
haptoglobin, apopliprotein A1 and 2-macroglobulin,
these analyses were not possible.
In summary, all of the serum fibrosis markers tested
correlated significantly with Ishak fibrosis stage on uni-
variate analysis among 513 patients entering the lead-in
phase of the HALT-C Trial. On multivariate analysis, a
3-variable model consisting of TIMP-1, HA, and platelet
count distinguished patients with noncirrhotic CHC
from those with cirrhosis. Also, this new model per-
formed significantly better than other models based on
routine laboratory tests, suggesting that serum fibrosis
markers provide useful, incremental information in esti-
mating disease stage in CHC. Contrary to expectations,
the serum marker panels did not correlate better with
quantitative hepatic collagen levels than with Ishak fibro-
sis scores. This observation may result from the limited
range of morphometry scores in our patients with CHC
who all had advanced fibrosis. In addition, our findings
suggest that the pattern of fibrosis distribution as deter-
mined by light microscopy may be linked more faithfully
to the severity of chronic liver diseases such as CHC than
the hepatic collagen content determined by computerized
morphometry.
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